MedTrace Logo

CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris

NCT02189629 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 453

Last updated 2019-11-14

Study results available
· View outcomes & findings →

Summary

Multi-center, open-label, non-comparative safety and efficacy study with 52 Weeks of treatment on the face and trunk for acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

DRUG

CD5789 (trifarotene)

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Kevin Chan · Galderma R&D

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-23
Primary Completion
2017-02-23
Completion
2017-02-23

Countries

  • United States
  • Czechia
  • Germany
  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189629 on ClinicalTrials.gov